Journal: Oncotarget

Article Title: Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells

doi: 10.18632/oncotarget.19436

Figure Lengend Snippet: Viability of U937 cells and R-U937 cells (A) and of HL-60 cells and R-HL-60 cells (B) after treatment with teriflunomide (TFN) for 72 h. The p -values are indicated. N.S. indicates nonsignificant results of the t -test following two-way ANOVA. The results of three independent experiments are shown. (C) Analysis of EU availability in R-U937 cells (left panel) and R-HL-cells (right panel) without and with 1 μM TFN treatment for 72 h. Green lines: without treatment; red lines: with treatment. (D) Relative mRNA expression levels of UCK1 and UCK2 normalized with the mRNA expression level of ACTB in R-U937 and R-HL-60 cells without and with 1 μM TFN treatment for 72 h. The results of three independent experiments are shown.

Article Snippet: AZA and DAC were purchased from Wako Pure Chemical Industries (Osaka, Japan) and teriflunomide from Selleck Chemicals (Houston, TX, USA).

Techniques: Expressing

Journal: Oncotarget

Article Title: Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells

doi: 10.18632/oncotarget.19436

Figure Lengend Snippet: Viability of U937 cells (A), HL-60 cells (B) , R-U937 cells (C) , and R-HL-60 cells (D) after treatment with AZA (0, 1, 5, 10 μM) for 72 h in the absence or presence of 1 μM teriflunomide (TFN). The p -values of significance are indicated. N.S. indicates nonsignificant results of the t -test and two-way ANOVA. The results of three independent experiments are shown.

Article Snippet: AZA and DAC were purchased from Wako Pure Chemical Industries (Osaka, Japan) and teriflunomide from Selleck Chemicals (Houston, TX, USA).

Techniques:

Journal: Oncotarget

Article Title: Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells

doi: 10.18632/oncotarget.19436

Figure Lengend Snippet: Analysis of apoptosis in R-U937 cells. (upper panels) and R-HL-60 cells (lower panels) of mock treatment, treatment with 10 μM AZA alone, treatment with 1 μM teriflunomide (TFN) alone, and combination treatment with AZA and TFN for 96 h.

Article Snippet: AZA and DAC were purchased from Wako Pure Chemical Industries (Osaka, Japan) and teriflunomide from Selleck Chemicals (Houston, TX, USA).

Techniques:

Journal: Oncotarget

Article Title: Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells

doi: 10.18632/oncotarget.19436

Figure Lengend Snippet: Viability of U937 and R-U937 cells (A) and HL-60 and R-HL-60 cells (B) after treatment with 0.2 μM DAC for 72 h in the absence or presence of 1 μM teriflunomide (TFN). The results of three independent experiments are shown.

Article Snippet: AZA and DAC were purchased from Wako Pure Chemical Industries (Osaka, Japan) and teriflunomide from Selleck Chemicals (Houston, TX, USA).

Techniques:

Journal: Oncotarget

Article Title: Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells

doi: 10.18632/oncotarget.19436

Figure Lengend Snippet: (A) Viability of leukemia cells from patients with AZA resistance after treatment with 1 μM AZA and/or 1 μM teriflunomide (TFN) for 24 h. * p < 0.01. (B) Viability of healthy CD34 + cells after treatment with 1 μM AZA and/or 1 μM TFN for 48 h.

Article Snippet: AZA and DAC were purchased from Wako Pure Chemical Industries (Osaka, Japan) and teriflunomide from Selleck Chemicals (Houston, TX, USA).

Techniques:

Journal: Oncotarget

Article Title: Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells

doi: 10.18632/oncotarget.19436

Figure Lengend Snippet: (A, B) The growth of U937 cells (A) and HL-60 cells (B) treated with 5 μM AZA and/or 1 μM teriflunomide (TFN) for 42 days. * p < 0.01 in comparison with mock or TFN-treated cells, # p < 0.01 in comparison with AZA-treated cells. (C, D) The AZA sensitivity of U-937 cells (C) and HL-60 cells (D) treated with 5 μM AZA and/or 1 μM TFN for 42 days.

Article Snippet: AZA and DAC were purchased from Wako Pure Chemical Industries (Osaka, Japan) and teriflunomide from Selleck Chemicals (Houston, TX, USA).

Techniques: Comparison

Journal: Therapeutic Drug Monitoring

Article Title: Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

doi: 10.1097/FTD.0000000000000302

Figure Lengend Snippet: Chromatogram of (A) blank DBS, (B) blank DBS spiked with IS, and (C) blank DBS spiked with teriflunomide at the LLOQ (0.01 mcg/mL), and IS.

Article Snippet: Teriflunomide and its internal standard (IS) [ 2 H 4 ]-teriflunomide were obtained from Toronto Research Chemicals Inc, (North York, ON, Canada).

Techniques:

Journal: Therapeutic Drug Monitoring

Article Title: Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

doi: 10.1097/FTD.0000000000000302

Figure Lengend Snippet: Influence of HCT on quantification of teriflunomide at low and high QC concentrations: linear regression with 95% mean CIs of bias depending on HCT level. AdjRsq, adjusted R square; L90M, lower 90% confidence limit for the mean; PRED, predicted value for % bias; Rsq, R square; RMSE, root mean square error; U90M, upper 90% confidence limit for the mean.

Article Snippet: Teriflunomide and its internal standard (IS) [ 2 H 4 ]-teriflunomide were obtained from Toronto Research Chemicals Inc, (North York, ON, Canada).

Techniques:

Journal: Therapeutic Drug Monitoring

Article Title: Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

doi: 10.1097/FTD.0000000000000302

Figure Lengend Snippet: Passing–Bablok relationship obtained from plotting plasma and DBS teriflunomide concentrations. Each symbol represents 1 subject. All data of the same subject are represented with the same symbol. Passing–Bablok regression: R 2 = 0.97, slope 0.60 [95% CI 0.58–0.61], intercept −0.04 (95% CI −0.15 to 0.01).

Article Snippet: Teriflunomide and its internal standard (IS) [ 2 H 4 ]-teriflunomide were obtained from Toronto Research Chemicals Inc, (North York, ON, Canada).

Techniques:

Journal: Therapeutic Drug Monitoring

Article Title: Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

doi: 10.1097/FTD.0000000000000302

Figure Lengend Snippet: DBS to plasma teriflunomide concentration over time. Each symbol represents 1 subject. All data of the same subject are represented with the same symbol. One ratio of 2.77 has not been shown for day 17.

Article Snippet: Teriflunomide and its internal standard (IS) [ 2 H 4 ]-teriflunomide were obtained from Toronto Research Chemicals Inc, (North York, ON, Canada).

Techniques: Concentration Assay

Journal: Expert opinion on therapeutic targets

Article Title: The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia

doi: 10.1080/14728222.2018.1536748

Figure Lengend Snippet: The landscape of DHODH inhibitors in 2018.

Article Snippet: Teriflunomide (Aubagio) , Sanofi Genzyme , FDA approved , Multiple sclerosis , .

Techniques: